"label","id","name","rationale","uuid:ID","description","instanceType"
"","StudyDesign_1","Study Design 1","The discontinuation rate associated with this oral dosing regimen was 58.6% in previous studies, and alternative clinical strategies have been sought to improve tolerance for the compound. To that end, development of a Transdermal Therapeutic System (TTS) has been initiated.","a3e74b7b-c578-489e-a52b-d2b80ab5ae08","The main design for the study","StudyDesign"
